Showing results (5601-5610 of 9,342) with videos related to
Sort By:
Pageof 935
Cancer Medicine|December 30, 2022
Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastomaStephen Ahn, Jae-Sung Park, Heewon Kim, et al.Cancer Medicine|December 30, 2022
MicroRNA 200a as a histologically independent marker for meningioma recurrence: Results of a four microRNA panel analysis in meningiomasSteffi Urbschat, Benjamin Landau, Nina-Christin Bewersdorf, et al.Cancer Medicine|December 30, 2022
Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignanciesSamane Abbasi, Milad Asghari Totmaj, Masoumeh Abbasi, et al.Cancer Medicine|July 5, 2022
Changes in the disease burden of breast cancer along with attributable risk factors in China from 1990 to 2019 and its projections: An analysis of the global burden of disease study 2019Jie Li, Cui Chen, Jinjin Nie, et al.Cancer Medicine|July 1, 2021
A prognostic nomogram based on competing endogenous RNA network for clear-cell renal cell carcinomaYun Peng, Shangrong Wu, Zihan Xu, et al.Cancer Medicine|June 23, 2021
Pivotal factors associated with the immunosuppressive tumor microenvironment and melanoma metastasisChuan Zhang, Dan Dang, Lele Cong, et al.Cancer Medicine|June 30, 2021
Immunophenotype-associated gene signature in ductal breast tumors varies by receptor subtype, but the expression of individual signature genes remains consistentMichael Behring, Yuanfan Ye, Amr Elkholy, et al.Cancer Medicine|June 30, 2021
Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based studyXiaofei Mo, Mingge Zhou, Hui Yan, et al.Cancer Medicine|June 30, 2021
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trialRiad Salem, Daneng Li, Nicolas Sommer, et al.Cancer Medicine|June 30, 2021
Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancerSandi L Pruitt, David E Gerber, Hong Zhu, et al.Pageof 935